CCK-8 assay results revealed that the decrease in ROCK2 levels enhanced the sensitivity of drug-resistant CCA cells to Pemigatinib; however, the addition of the ferroptosis inhibitor DFO blocked this process (Fig. 3A, B). The gene discussed is ROCK2; the disease is cholangiocarcinoma.